Biocon sells 1.88 percent stake in Syngene for Rs 230 crore
New Delhi: Biocon Ltd has sold close to 2% stake in its research arm Syngene International for an estimated Rs230 crore.
"Biocon, the promoter of Syngene International, on 16 May 2018 has sold 37,65,574 equity shares amounting to 1.88% of the equity share capital of Syngene through open market sale," Biocon said in a regulatory filing.
In a separate filing, Syngene said Biocon has sold the shares for achieving minimum public shareholding requirement.
Based on average weighted price of Syngene's shares on 16 May at Rs611.02 apiece, the transaction is estimated at Rs230.08 crore. Post-transaction, stake of promoter and promoter group in the company stands at 72.57%. Public shareholding is 25.90%.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd